Safety and immunogenicity of a new formulation of an inactivated hepatitis A vaccine

By Dagan R.   Greenberg D.   Goldenbertg-Gehtman P.   Vidor E.   Briantais P.   Pinsk V.   Athias O.   Dumas R.  

Vaccine, Vol. 17, Iss. 15, 1999-04 ,pp. : 1919-1925

Elsevier

Access to resources Recommend Favorite

An open study of subcutaneous administration of inactivated hepatitis A vaccine (VAQTA(R)) in adults: safety, tolerability, and immunogenicity

By Linglof T.   van Hattum J.   Kaplan K.M.   Corrigan J.   Duval I.   Jensen E.   Kuter B.  

Vaccine, Vol. 19, Iss. 28, 2001-07 ,pp. : 3968-3971

Elsevier

Access to resources Recommend Favorite

Erratum to ''An open study of subcutaneous administration of inactivated hepatitis A vaccine (VAQTA ( R)) in adults: safety, tolerability, and immunogenicity'' - [Vaccine 19 (2001) 3968-3971]

By Linglof T.   Hattum J.v.   Kaplan K.M.   Corrigan J.   Duval I.   Jensen E.   Kuter B.  

Vaccine, Vol. 20, Iss. 1, 2001-10 ,pp. : 281-281

Elsevier

Access to resources Recommend Favorite

Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial

By Holzer B.R.   Hatz C.   Schmidt-Sissolak D.   Gluck R.   Althaus B.   Egger M.  

Vaccine, Vol. 14, Iss. 10, 1996-07 ,pp. : 982-986

Elsevier

Access to resources Recommend Favorite

Safety, immunogenicity and antibody persistence of an inactivated hepatitis A vaccine in 4 to 15 year old children

By Castillo de Febres O.   Chacon de Petrola M.   Casanova de Escalona L.   Naveda O.   Naveda M.   Estopinan M.   Bordones G.   Zambrano B.   Garcia A.   Dumas R.  

Vaccine, Vol. 18, Iss. 7, 1999-11 ,pp. : 656-664

Elsevier

Access to resources Recommend Favorite